1. Highlights of prescribing information adjust adult doses every 2 to 4 ... (n.d.-b). https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/207620s018lbl.pdf
2. Sacubitril-Valsartan - StatPearls - NCBI Bookshelf. (n.d.-c). https://www.ncbi.nlm.nih.gov/books/NBK507904/
3. Cipla Ltd. Azmarda Tablets (Sacubitril/Valsartan). Ciplamed. [Revised in March 2017] https://www.ciplamed.com/content/azmarda-tablets
4. KD Tripathi MD. Cardiovascular drugs. Essentials of Medical Pharmacology. Seventh Edition. New Delhi, May 2013. Page – 508.
5. Loretta Fala. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Patients with Heart Failure. NCBI; PMC. Pubmed Central. National Library of Medicine, National Institute of Health. September 2018. [cited 2023 July 21]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4636283/
6. Peter Khalil, Ghazal Kabbach, Sarmad Said and Debabrata Mukherje. Entresto, a New Panacea for Heart Failure. NIH National Library of Medicine, National centre for biotechnology information. Pubmed.gov. 2018. [cited 2023 July 21]. Available from: https://pubmed.ncbi.nlm.nih.gov/29532764/